Market Research Logo

Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026

Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026

Diabetes, considered to be the most common metabolic disorder in humans, is ranked among the top ten fatal diseases in the US. The increasing incidence, growing prevalence and the progressive nature of the disease has spurred several pharmaceutical companies to develop novel approaches / therapies to provide better treatment options for diabetic patients worldwide. While insulin supplements and insulin based therapies represent a major portion of the anti-diabetic drugs market, non-insulin therapies are first line therapies designed especially for patients suffering from type II diabetes.

Sulfonylureas, biguanides, glinides, TZDs and alpha- glucosidase inhibitors were the first classes of non-insulin therapies to hit the market. Subsequently, incretin based therapies, such as GLP-1 agonists and DPP4 inhibitors, emerged as the standard of care for the treatment of type II diabetes. More recently, SGLT2 inhibitors have also been identified as an effective treatment solution for the same patient population. These three classes have captured a significant portion of the overall anti-diabetes market in a relatively short time span.

GLP-1 agonists and DPP4 inhibitors were introduced in the market over a decade ago while the first SGLT2 inhibitor was approved only in 2012. A number of drugs have emerged as blockbusters; examples include VICTOZA® (GLP-1 agonist), JANUVIA® / JANUMET® (DPP4 inhibitor) and INVOKANA® / INVOKAMET® (SGLT2 inhibitor).

Several companies, including both big pharmaceutical players and small to mid-sized companies, are active in this area. Companies engaged in developing anti-diabetic drug classes have actively entered into collaborations with other stakeholders to either acquire / develop / commercialize candidate therapies or for technology licensing. For instance, Tobira acquired the exclusive rights to develop and commercialize evogliptin from Dong-A ST in April 2016; Eli Lilly and Sumitomo Dainippon Pharma entered into a sales collaboration agreement for Trulicity® in July 2015; Novo Nordisk in-licensed Zosano’s technology to develop a transdermal patch formulation of Novo’s GLP-1 analogs, including semaglutide in February 2014; Takeda and Sanofi signed a co-promotion agreement for alogliptin in China in April 2013.

Recently issued FDA warnings specifically for DPP4 and SGLT2 inhibitors are likely to impact their adoption. However, new advances in drug development and the introduction of novel technologies are expected to help stakeholders operate within a proper framework and work towards eliminating the current gaps.

EXAMPLE HIGHLIGHTS
1. With a current total / combined share of more than 70% in the overall non-insulin market, GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors represent the three most prominent anti-diabetic drug classes. In terms of size, currently, the market of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors is worth over USD 4 billion, USD 10 billion and USD 2 billion respectively. Overall, the market is highly fragmented and well distributed across different regions.

2. Combined, the three drug classes have over 20 approved drugs (accounting around 40 different formulations / fixed-dose combinations) for the treatment of type II diabetes. In addition, the clinical / preclinical pipeline is rich and has over 70 molecules in different stages of development. Of the three classes, DPP4 inhibitors currently has the maximum number of marketed drugs (over 10, excluding fixed-dose combinations). On the other hand, GLP-1 agonists represent the most active class of drugs with over 40 molecules under development. SGLT2 inhibitors are also emerging at a rapid pace and already have six marketed drugs across different regions. Semaglutide (Novo Nordisk), ITCA 650 (Intarcia Therapeutics), sotagliflozin (Sanofi / Lexicon Pharmaceuticals), ertugliflozin (Merck / Pfizer), retagliptin (Jiangsu Hengrui Medicine) and gosogliptin (SatRx / Pfizer) are examples of late stage drugs that are likely to receive approval in the near future.

3. Overall we came across over 80 pharmaceutical companies actively engaged in the discovery, development and commercialization of non-insulin therapies. Established pharmaceutical players have captured a major share of the non-insulin anti-diabetic drugs market. In fact, AstraZeneca, BMS, Eli Lilly and Sanofi are developing non-insulin therapies across all the three drug classes. Several other companies such as Daiichi Sankyo, Janssen, Merck, Mitsubishi Tanabe Pharma, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda and Zealand Pharma have invested heavily in the development of multiple molecules belonging to these drug classes. A number of start-ups / small companies such as (in alphabetical order) Alteogen, Amunix, ArisGen, C4XD, Diartis Pharmaceuticals, Oramed Pharmaceutical, PegBio, Poxel, Rani Therapeutics, Receptos, SatRx, Sirona Biochem and Spitfire Pharma have entered this space and are also competing to gain a significant share in the overall non-insulin therapies market.

4. In addition to increased competition of such therapies in the major geographies such as the US and EU, some stakeholders have focused on tapping a localized opportunity. Drugs such as teneligliptin (Mitsubishi Tanabe Pharma), trelagliptin (Takeda), ipragliflozin (Astellas Pharma/ Kotobuki Pharmaceutical) and luseogliflozin (Taisho Pharmaceutical) have been approved only in Japan. Similarly, retagliptin (Jiangsu Hengrui Medicine) and Uni-E4 (Uni-Bio Science Group) are in Phase III clinical development in China only.

5. With a vision to increase patient compliance, several pharmaceutical companies have introduced fixed-dose formulations of different drugs. Prominent examples include Eucreas® / Galvumet® / Galvus Met® / Icandra® / Zomarist® (vildagliptin + metformin) (Novartis), INVOKAMET® / VOKANAMET® (canagliflozin + metformin) (Janssen Pharmaceutical Companies / Mitsubishi Tanabe Pharma / Daiichi Sankyo), JANUMET® / Velmetia® (sitagliptin + metformin) (Merck), Xigdua® (dapagliflozin + metformin) (Astra Zeneca / BMS) and Xultophy® / IDegLira (liraglutide + insulin degludec) (Novo Nordisk).

6. Technological advancements are amongst the key future growth drivers. Drug developers are investigating new routes of administration using several innovative technology platforms, such as Axcess™ (Diabetology), Eligen® (Emisphere Technologies), PharmFilm® Technology (MonoSol Rx) and the Protein Oral Delivery (POD™) technology (Oramed Pharmaceuticals), to facilitate the oral administration of GLP-1 agonists. Other innovative technologies such as the Intravail® drug delivery platform are attempting to facilitate nasal administration. Companies such as ScinoPharm and Panacea Biotech are developing oral capsule formulations of DPP4 inhibitors. Their molecules, DBPR108 and PBL 1427, respectively, are still in the early stages of clinical development. SGLT2 inhibitors, primarily used to treat type II diabetes, are also being developed for the treatment of type I diabetes. Examples include sotagliflozin (Theracos) and remogliflozin (BHV Pharma).

7. Dual agonist drugs are also being developed to provide more effective treatment options. Examples of molecules that target both the GLP-1 receptor and glucagon receptor include MK-8521 (Merck), TTP401 / LY2944876 (Transition Therapeutics / Eli Lilly), MEDI0382 (AstraZeneca), SAR425899 (Sanofi) and MOD-6030 / MOD-6031 (OPKO Biologics). On the other hand, NN9709 (Novo Nordisk) and SAR438335 (Sanofi) are being developed to act on both GLP-1 and GIP receptors.

8. Several research institutes, companies and organization have made significant contribution to the discovery and overall development of these therapies. During the study, we identified over 400 key opinion leaders who have played critical role in the development of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors. In addition, we identified over 50 articles, published during the 12 months beginning January 2015, which focused on these three drug classes. The design of these studies primarily focussed on evaluating the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of the drugs.

9. Extensive efforts are being made by pharmaceutical companies to explore new and innovative therapeutic strategies and agents that are safer and more effective than the already available options. Many novel non-insulin therapies are under clinical development. Examples of these new anti-diabetic drug classes include glucokinase activators, GPR119 agonists, GCGR antagonists, 11-beta hydroxysteroid dehydrogenase type 1 inhibitors, glycogen phosphorylase inhibitors and PTP-1B antagonists.

10. It is important to highlight that nearing patent expiries of currently available drugs and the potential health hazards associated with the use of some of these inhibitors are going to negatively impact the market growth. However, our overall outlook is highly promising. We believe that SGLT2 inhibitors are likely to grow at an annualized growth rate of ~17%, followed by GLP-1 agonists (expected growth rate of ~13.4%).

SCOPE OF THE REPORT
The “Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016-2026” report provides a comprehensive analysis of the current market landscape of these therapies and an informed opinion on how the market is likely to evolve over the next decade. The anti-diabetic drugs market broadly comprises of insulin and non-insulin therapies. Non-insulin therapies are further classified under various categories based on their respective mechanisms of action. Of the different types of non-insulin therapies, GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors have been the most popular in the last few years. As mentioned earlier, these therapeutic classes have captured the attention of a number of pharmaceutical companies and drug developers worldwide. Several companies, including pharmaceutical giants, mid-sized players and start-ups, have come up with innovative technologies and novel formulations of these drug classes. Such advances have generated and sustained significant momentum in this segment of the industry. Specifically, GLP-1 agonists, which have been researched for several years, have a rich pipeline of clinical and preclinical molecules. DPP4 inhibitors currently have a relatively larger market share; however, they are now giving way to other relatively newer and emerging classes such as SGLT2 inhibitors.

During the course of our study, we identified over 80 molecules belonging to these three drugs classes. More than 70% of the candidates are currently under clinical / preclinical development; the efforts are actively being led by several companies. Focused primarily on these three classes of drugs, this report features:
An overview of the market landscape highlighting important details on each molecule such as key players, current phase of product development, route of administration and dosage regime.
Detailed profiles of drugs that have been recently approved / marketed or are in the late stages of development.
A list of key opinion leaders (KOLs) who were involved in the discovery and development of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors.
An analysis of recently published clinical trial data depicting the prevalent trends and technical developments that have taken place in the industry.
A discussion on the potential side effects and warnings issued by regulatory authorities suggesting areas of improvement / guidance for future drug development.
A list of upcoming non-insulin novel therapies that are currently in early stages of development and likely to become a part of the anti-diabetic drugs market in the near future.
The report also provides an estimate of the likely future size of the non-insulin therapies for diabetes. Our forecast model was built based on an understanding of the existing market trends and likely future opportunities for GLP-1 agonists, DPP4 inhibitors, SGLT2 inhibitors and other non-insulin anti-diabetic drug classes. We have provided informed estimates of the expected future sales of marketed and late stage product candidates under each category, highlighting their share in the overall market over the next ten years.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. Unless otherwise specified, all financial figures are presented in USD.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors during the coming decade.

Chapter 3 provides a general introduction to diabetes and discusses associated symptoms, available diagnostic methods and tests, and other complications associated with the condition. It also includes a detailed classification of the various therapeutic interventions available for the treatment of diabetes. These include both insulin based and non-insulin therapies. The chapter also provides brief descriptions of their respective mechanisms of action.

Chapter 4 provides a comprehensive overview of the market landscape of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors. It includes information on over 100 different molecules that fall under these classes of drugs. Some of these are already approved and are available in different regions across the globe. The rest are currently in various stages of preclinical / clinical development. The chapter presents analysis of the molecules based on their current phase of development, the various routes of administration being considered for their systemic delivery, dosage frequency, type of molecule and key players involved in developing these molecules.

Chapter 5 contains detailed profiles of recently approved and late stage GLP-1 agonists. Each profile covers information on several aspects of these drugs such as their history of development, clinical trial results, dosage form and regime, recent sales of the product (for marketed drugs), the current status of development, and the collaborations and partnerships that have been inked related to that particular drug / drug candidate.

Chapter 6 contains detailed profiles of recently approved and late stage DPP4 inhibitors. Each profile covers information on several aspects of these drugs such as their history of development, clinical trial results, dosage form and regime, recent sales of the product (for marketed drugs), the current status of development, and the collaborations and partnerships that have been inked related to that particular drug / drug candidate.
Chapter 7 contains detailed profiles of recently approved and late stage SGLT2 inhibitors. Each profile covers information on several aspects of these drugs such as their history of development, clinical trial results, dosage form and regime, recent sales of the product (for marketed drugs), the current status of development, and the collaborations and partnerships that have been inked related to that particular drug / drug candidate.

Chapter 8 focusses on the various side effects reported by patients treated using these drugs. It includes detailed discussions on the potential complications that may arise upon using these drugs, and the warnings issued by the FDA and other regulatory bodies regarding the associated risks. In addition, the chapter lists the various GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors that have been terminated during development due to various reasons.

Chapter 9 provides a brief introduction to other novel interventions that are currently being investigated as potential treatment options for diabetes. The chapter also includes an analysis of these novel therapeutic options based on the type of molecule being investigated and phase of development.

Chapter 10 provides a detailed analysis on the likely future size of the non-insulin therapies market over the next decade. It presents comprehensive forecast scenarios for each individual drug class mentioned in the report, namely GLP-1 agonists, DPP4 inhibitors, SGLT2 inhibitors and other non-insulin anti-diabetic drugs.

Chapter 11 presents an analysis of the Key Opinion Leaders (KOLs) in this domain. It contains schematic representations of world maps highlighting the geographical locations of these eminent scientists / researchers. The chapter presents a detailed 2X2 analysis to assess the relative experience of certain KOLs based on the number of clinical studies they participated in and the highest phase of development they investigated.

Chapter 12 provides a detailed analysis of recently published clinical data on GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors. It identifies various aspects of the ongoing research and presents analysis highlighting the active drugs, study focus areas and clinical endpoints (safety / efficacy / tolerability / pharmacodynamics / pharmacokinetics) across the published data.

Chapter 13 is a collection of interview transcripts of the discussions we held with key stakeholders in the industry.

Chapter 14 summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report.
1 3sBio
2 Aalborg Hospital
3 Aarhus University Hospital
4 Abbott Laboratories
5 ActivX Biosciences
6 Addex Therapeutics
7 Aegis Therapeutics
8 AGDUC
9 AIDS Clinical Trials Group
10 Ajinomoto
11 Alantos Pharmaceuticals
12 Albert Einstein College of Medicine
13 Alize Pharma
14 Alkem Labs
15 Alkermers
16 Allegheny Health Network
17 Allergan
18 Almirall
19 Alteogen
20 ALZA Pharmaceuticals
21 American Association of Clinical Endocrinologists
22 American Diabetes Association
23 American Heart Association
24 Amgen
25 Amunix
26 Amylin Pharmaceuticals
27 AntriaBio
28 ArisGen
29 Arisaph Pharmaceuticals
30 Asan Medical Center
31 Ascendis Pharma
32 Assistance Publique Hopitaux De Marseille
33 Astellas Pharma
34 AstraZeneca
35 Atlanta VA Medical Center
36 Audie L. Murphy VA Hospital
37 Aventis
38 Avexxin
39 Banyu Pharmaceutical
40 Bayer Pharmaceuticals
41 Baylor College of Medicine
42 Baylor Research Institute
43 Beijing Tongren Hospital
44 Besançon Regional University Hospital
45 Beth Israel Deaconess Medical Center
46 BHV Pharma
47 Bio-Ker
48 Biolaxy
49 BioLineRx
50 Birmingham City Hospital
51 Bispebjerg Hospital
52 Boehringer Ingelheim
53 Boramae Medical Center
54 Boston Medical Center
55 Brigham and Women's Hospital
56 Bristol-Myers Squibb
57 C4XD
58 Cadila Healthcare Limited
59 Cambridge Healthtech Institute
60 Carl T. Hayden Medical Research Foundation
61 Cedars-Sinai Medical Center
62 Celerion
63 Celgene
64 CellMed
65 Center for Human Drug Research
66 Centers for Disease Control and Prevention
67 Centre for Prognosis Studies in the Rheumatic Diseases
68 Centre Hospitalier De Valenciennes
69 Centre Hospitalier Sud Francilien
70 Centre Hospitalier Universitaire Amiens
71 Centro de Diabetes Curitiba
72 CERITD
73 Chang Gung Memorial Hospital
74 Charles Drew University of Medicine and Science
75 Charles University
76 ChemRar High Tech Center
77 Children's Healthcare of Atlanta
78 Children's Heart Surgery Fund
79 Children's Hospital of Philadelphia
80 China-Japan Friendship Hospital
81 Chinese PLA General Hospital
82 Chinese University of Hong Kong
83 Chonbuk National University Hospital
84 CHU de Québec
85 CHU Dijon
86 Chugai Pharmaceutical
87 Cincinnati Children's Hospital Medical Center
88 Clinical Pharmacology Unit, Belgium
89 Clinique Saint-Anne Strasbourg
90 Clinique Sainte-Anne - AURAL Strasbourg
91 Colorado State University
92 Committee for Medicinal Products for Human Use
93 ConjuChem Biotechnologies
94 Connexios Life Sciences
95 Copenhagen University Hospital
96 Cornell CRS
97 CoSynance Therapeutics
98 CSL Behring
99 CSPC Pharma
100 CureDM
101 CymaBay Therapeutics
102 Daewoong Pharmaceutical
103 Daiichi Sankyo
104 Dainippon Sumitomo Pharma
105 Dance Biopharm
106 Diabetes Foundation
107 Diabeteszentrum Bad Lauterberg
108 Diabetes-Zentrum Quakenbruck
109 Diabetology
110 Diamyd Medical
111 Diartis Pharmaceuticals
112 Dokkyo Medical University
113 Dong-A Pharmaceutical
114 Dongguk University College of Medicine
115 Double-Crane Pharmaceutical
116 Dr. A. Ramachandran's Diabetes Hospital
117 Duke University
118 Eisai
119 Eli Lilly
120 Emisphere Technologies
121 Emory University
122 Eurofarma
123 European Association for the Study of Diabetes
124 Farallon Capital Management
125 Federal University of Rio Grande do Sul
126 Ferring Pharmaceutical
127 Flamel Technologies
128 Foresee Pharmaceuticals
129 Foresite Capital
130 Forest Laboratories
131 Franklin Templeton
132 Fred Alger Management
133 Friedrich-Alexander-Universität Erlangen-Nürnberg
134 Fudan University
135 Fundação Faculdade Regional de Medicina de São José do Rio Preto
136 Fuwai Hospital
137 GalaxoSmithKline
138 Gastroenterology Department Erasme Hospital
139 General Hospital of People's Liberation Army Chengdu Military Region
140 Genexine
141 Gentofte Hospital
142 Genzyme
143 Geropharm
144 Glasgow Royal Infirmary
145 Glenmark Pharmaceuticals
146 Glide Technologies
147 Grady Memorial Hospital
148 Greensboro CRS
149 Guy's and St Thomas' Hospitals
150 GWT-TUD
151 Hadassah Ein Kerem
152 Hadassah Medical Organization
153 Handok Pharmaceuticals
154 Hanmi Pharmaceuticals
155 Harvard University
156 Hatter Cardiovascular Institute
157 Haywood Regional Medical Center
158 Heart Institute (InCor)
159 Hebrew University
160 Herlev Hospital
161 Hopital cardiologique Louis Pradel
162 Hospices Civils de Colmar
163 Hospital Clinic of Barcelona
164 Hospital Clínico de Madrid
165 Hospital General Carlos Haya
166 Hospital General de Segovia
167 Hospital of the Holy Cross and Saint Paul
168 Hospital Universitario Insular
169 Houston AIDS Research Team CRS
170 Hua Medicine
171 Huashan Hospital
172 Hvidovre University Hospital
173 Hyundai Pharmaceutical
174 Ildong Pharmaceutical
175 Ilsan Hospital
176 ImmuPharma
177 Imperial College London
178 Indiana University
179 Institut de Recherches Cliniques de Montreal
180 Institut für Pharmakologie und Präventive Medizin
181 Institut National de la Santé Et de la Recherche Médicale
182 Institute for Medical Research
183 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
184 Intarcia Therapeutics
185 Intercept Pharmaceuticals
186 International Diabetes Federation
187 International Society for Pharmacoeconomics and Outcomes Research
188 Ionis Pharmaceuticals
189 Ipsen
190 IRCCS Policlinico San Matteo Foundation
191 Islet Lifesciences
192 Janssen
193 Jean Verdier Hospital
194 JHL Biotech
195 Jiangsu Hansoh Pharmaceutical
196 Jiangsu Hengrui Medicine
197 Jiangsu Provincial People's Hospital
198 Johnson and Johnson
199 Joslin Diabetes Center
200 Jothydev's Diabetes and Research Center
201 Juntendo University School of Medicine
202 Juvenile Diabetes Research Foundation
203 Kalypsys
204 Kanazawa University
205 Kangbuk Samsung Hospital
206 Kansai Electric Power Hospital
207 Karolinska Institutet
208 Katobuki Pharmaceutical
209 Kevan Herold
210 Khoo Teck Puat Hospital
211 Kinderkrankenhaus auf der Butl
212 KineMed
213 King's College London
214 Kirchhain
215 Kissei Pharmaceutical
216 Koege University Hospital
217 Korea University
218 Kotobuki Pharmaceutical
219 Kowa Pharmaceutical
220 Kurume University
221 Kyorin Pharmaceutical
222 Kyoto University
223 Kyowa Hakko Kirin Company
224 Kyunghee University Medical Center
225 Laval University
226 Leicester General Hospital
227 Leiden University Medical Center
228 Lexicon
229 LG Life Sciences
230 Ligand Pharmaceuticals
231 Lund University
232 Lunenfeld Tanenbaum Research Institute
233 Lupin
234 Luye Pharma Group
235 Mackay Memorial Hospital
236 MacroGenics
237 Mannkind Corporation
238 Marcadia Biotech
239 Massachusetts General Hospital
240 Mayo Clinic
241 Medanta Medicity
242 Medical College of Wisconsin
243 Medical University Innsbruck
244 Medical University of Graz
245 Medical University of Silesia
246 Medical University of Vienna
247 Medico Moving Center Institute, Formosa
248 MedImmune
249 Menarini Group
250 Merck
251 Merrion Pharmaceuticals
252 Metabasis Therapeutics
253 Metabolic Center of Louisiana Resarch Foundation
254 Mid America Heart Institute Saint Luke's Health System
255 MidaSol Therapeutics
256 Mitsubishi Tanabe Pharma
257 Mitusui Memorial Hospital
258 MonoSol Rx
259 Mount Sinai Hospital, Canada
260 Mountain Diabetes and Endocrine Center
261 MultiMedica
262 Nanjing Drum Tower Hospital
263 National Cerebral and Cardiovascular Center
264 National Health Research Institutes
265 National Institues of Health
266 National Institute for Health and Care Excellence
267 National Institute of Diabetes and Digestive and Kidney Diseases
268 National Institute on Aging
269 National Taiwan University Hospital
270 Nemours Children's Clinic
271 New Enterprise Associates
272 New Leaf Venture Partners
273 New York Obesity Nutrition Research Center
274 NIHR Exeter Clinical Research Facility
275 Nobel İlaç'
276 NOD Pharmaceuticals
277 Norwegian University of Science and Technology
278 Novartis
279 Novo Nordisk
280 NU Hospital Organization
281 Numab
282 OctoPlus
283 Ohio State University
284 Ono Pharmaceutical
285 OPKO Biologics
286 Optum
287 Oramed Pharmaceuticals
288 Örebro University
289 Oregon Health and Science University
290 Osaka University Graduate
291 Oslo University Hospital Ullevaal
292 Otsuka Pharmaceutical
293 Panacea Biotec
294 PAREXEL International
295 Park Nicollet International Diabetes Center
296 PegBio
297 Peking Union Medical College Hospital
298 Pennington Biomedical Research Center
299 People's Hospital, Peking Universty
300 Peptron
301 Pfizer
302 Pharmaceutical Product Development
303 PharmaIN
304 Pharmsynthez
305 PhaseBio Pharmaceuticals
306 Phenomix
307 Phoenix VA Healthcare System
308 Phoundry Pharmaceuticals
309 Pitié-Salpêtrière Hospital
310 Palatin Technologies
311 Pontificia Universidad Catolica de Chile
312 Population Health Research Institute
313 Post Graduate Institute of Medical Education and Research
314 Poxel
315 Prism Research
316 Probiodrug
317 Profil Institut für Stoffwechselforschung
318 Profil Institute for Metabolic Research
319 Prosidion
320 Pusan National University Hospital
321 Pusat Perubatan Universiti Kebangsaan
322 Qianfoshan Hospital
323 Quilvest
324 Quintiles
325 Quotient Bioresearch Clinical Services
326 RA Capital
327 Radboud University
328 Rani Therapeutics
329 Receptos
330 Rigshospitalet
331 Rikshospitalet Medical Center
332 Roche
333 Royal Adelaide Hospital
334 Royal Bournemouth Hospital
335 Royal Devon & Exeter NHS Trust
336 Royal Surrey County Hospital
337 Royalty Pharma
338 Ruhr-University Bochum
339 Saint Luke's Mid America Heart Institute
340 Samsung Medical Center
341 Sana Klinikum Offenbach
342 Sanofi
343 Sanwa Kagaku Kenkyusho
344 Sao Paulo General Hospital
345 SatRx
346 Scientisic Research Institute of Cardiology and Internal Diseases
347 ScinoPharm
348 Seattle Children's Hospital
349 Second University of Naples
350 Second Xiangya Hospital of Central South University
351 Seoul National University Bundang Hospital
352 Seoul St. Mary's Hospital
353 Serometrix
354 Services Hospital
355 Servier
356 Severance Hospital
357 Shandong Provincial Hospital
358 Shanghai Jiao Tong University School of Medicine
359 Shanghai Mental Health Center
360 Shanghai Sixth People's Hospital
361 Sheba Medical Center
362 Sirona Biochem
363 Slotervaart Hospital
364 Spitfire Pharma
365 St Michael's Hospital
366 St. Josef Hospital
367 St. Joseph's Health Care, London
368 Stanford University
369 Stendhal
370 Steno Diabetes Center
371 Sumitomo Dainippon Pharma
372 Sun Pharma Advanced Research
373 Sun Yat-Sen University
374 Sydney Diabetes Centre
375 Taichung Veterans General Hospital
376 Taipei Medical University WanFang Hospital
377 Taisho Pharmaceutical
378 Takeda
379 Tampere University Hospital
380 Tarix Pharmaceuticals
381 Teijin Pharma
382 Teva Active Pharmaceutical Ingredients
383 The Baupost Group
384 The Catholic University of Korea
385 The First Affiliated Hospital of Xi’an Jiaotong University
386 The First Affiliated Hospital of Xiamen University
387 The First Affiliated Hospital of Zhejiang University
388 The George Institute for Global Health
389 The George Washington University Medical Faculty Associates
390 The National Center for Scientific Research
391 The Third Xiangya Hospital of Center South University
392 Theracos
393 Therapix Biosciences
394 Theratechnologies
395 Third Military Medical University, China
396 Thomas Jefferson University
397 TIMI Study Group
398 Tobira Therapeutics
399 Tolerx
400 Toronto Western Hospital
401 Transition Therapeutics
402 TransTech Pharma
403 Tulane University
404 Turku PET Centre
405 Turku University Hospital
406 UCL Institute of Neurology
407 UKMMC
408 UMass Medical School
409 Uni-Bio Science Group
410 Universität zu Lübeck
411 Université de Lorraine
412 Université de Montréal
413 University at Buffalo
414 University College Dublin
415 University Health Network
416 University Hospital Center of Toulouse
417 University Hospital of Basel
418 University Hospital of Caen
419 University Hospital of Palermo
420 University Medical Center Groningen
421 University Medical Center Hamburg-Eppendorf
422 University Medical Center Ljubljana,Slovenia
423 University Nijmegen Medical Center
424 University of Aarhus
425 University of Adelaide
426 University of Alabama at Birmingham
427 University of Alberta
428 University of Amsterdam
429 University of Birmingham
430 University of Bordeaux
431 University of British Columbia
432 University of California
433 University of California, Davis
434 University of California, Los Angeles
435 University of Chicago
436 University of Cincinnati
437 University of Colorado
438 University of Copenhagen
439 University of Dundee
440 University of Exeter
441 University of Geneva
442 University of Guadalajara
443 University of Illinois at Chicago
444 University of Leicester
445 University of Manchester
446 University of Maryland
447 University of Miami
448 University of Michigan
449 University of Minnesota
450 University of Munich
451 University of Nebraska-Lincoln
452 University of Nevada School of Medicine
453 University of North Carolina, Chapel Hill
454 University of Nottingham
455 University of Oulu
456 University of Padova Medical School
457 University of Palermo
458 University of Pennsylvania
459 University of Pittsburgh
460 University of São Paulo General Hospital
461 University of Southern California
462 University of Surrey
463 University of Tartu
464 University of Texas
465 University of Texas Health Science Center
466 University of Texas Medical Branch
467 University of the Ryukyus
468 University of Tokyo
469 University of Toronto
470 University of Washington
471 University of Western Ontario
472 Uppsala University
473 UT Southwestern Medical Center
474 VA Puget Sound Health Care System
475 Vall d'Hebron Research Institute
476 Vanderbilt University School of Medicine
477 Velocity Pharmaceutical Development
478 Venrock
479 Viking Therapeutics
480 Vitae Pharmaceuticals
481 VIVUS
482 vTv Therapeutics
483 VU University Medical Center
484 Wake Forest University / Wake Forest University Health Sciences
485 Walter Reed Army Medical Center- Diabetes Institute
486 Wan Fang Hospital
487 Wanbang Biopharmaceuticals (subsidiary of Shanghai Pharmaceutical Group)
488 Washington University CRS
489 Washington University School of Medicine
490 Woman's Hospital
491 World Health Organization
492 Wuhan General Hospital of Guangzhou Command
493 Xenetic Biosciences
494 Yale University
495 Yeshiva University
496 Yokohama City University School of Medicine
497 Yuhan
498 Zealand Pharma
499 Zosano Pharma
500 Zydus Cadila
501 ZymoGenetics


1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. Diabetes: Introduction
3.2.1. Diabetes: Classification
3.2.2. Diabetes: Symptoms
3.2.3. Diabetes: Diagnosis
3.2.4. Diabetes: Associated Health Risks / Complications
3.2.5. Diabetes: Therapies
3.2.5.1. Insulin Therapies
3.2.5.2. Non-Insulin Therapies
3.2.5.2.1. Alpha-glucosidase Inhibitors
3.2.5.2.2. Amylin Agonists
3.2.5.2.3. Biguanides
3.2.5.2.4. Dipeptidyl peptidase-4 (DPP4) inhibitors
3.2.5.2.5. Glinides / Meglitinides
3.2.5.2.6. GLP-1 Analogs / GLP-1 Agonists
3.2.5.2.7. Sodium-glucose cotransporter 2 (SGLT2) Inhibitors
3.2.5.2.8. Sulfonylureas
3.2.5.2.9. Thiazolidinediones (or ‘glitazones’or TZDs)
4. Market Overview
4.1. Chapter Overview
4.2. Non-Insulin Anti-Diabetic Therapies: History of Development / Evolution Timeline
4.3. GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors: Overall Market Overview
4.4. GLP-1 Agonists: Current Market Landscape
4.4.1. GLP-1 Agonists: Approved Drugs
4.4.2. GLP-1 Agonists: Pipeline Drugs
4.4.3. GLP-1 Agonists: Key Players
4.4.4. GLP-1 Agonists: Distribution by Route of Administration
4.4.5. GLP-1 Agonists: Distribution by Dosage Frequency
4.4.6. GLP-1 Agonists: Distribution by Type of Molecule
4.5. DPP4 Inhibitors: Current Market Landscape
4.5.1. DPP4 Inhibitors: Approved Drugs
4.5.2. DPP4 Inhibitors: Pipeline Drugs
4.5.3. DPP4 Inhibitors: Key Players
4.5.4. DPP4 Inhibitors: Distribution by Type of Therapy
4.5.5. DPP4 Inhibitors: Distribution by Dosage Frequency
4.6. SGLT2 Inhibitors: Current Market Landscape
4.6.1. SGLT2 Inhibitors: Approved Drugs
4.6.2. SGLT2 Inhibitors: Pipeline Drugs
4.6.3. SGLT2 Inhibitors: Key Players
4.6.4. SGLT2 Inhibitors: Distribution by Type of Therapy
4.6.5. SGLT2 Inhibitors: Distribution by Dosage Frequency
4.7. GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors: Key Players
5. GLP-1 Agonists
5.1. Chapter Overview
5.2. Albiglutide (GSK)
5.2.1. Product Overview
5.2.2. History of Development
5.2.3. Dosage Form, Regimen and Price
5.2.4. Historical Sales
5.2.5. Current Status of Development
5.2.6. Key Clinical Trial Results
5.2.6.1. Harmony 1 Study (Abstract Number: 2013-LB-5644)
5.2.6.2. Harmony 2 Study (Abstract Number: 2013-LB-5749)
5.2.6.3. Harmony 3 Study (Abstract Number: 2013-LB-5750)
5.2.6.4. Harmony 4 Study (Abstract number: 2013-LB-5751)
5.2.6.5. Harmony 5 Study (Abstract Number: 2013-LB-5752)
5.2.6.6. Harmony 6 Study
5.2.6.7. Harmony 7 Study
5.2.6.8. Harmony 8 Study
5.2.7. Recent Collaborations
5.3. Dulaglutide (Eli Lilly / Sumitomo Dainippon Pharma)
5.3.1. Product Overview
5.3.2. History of Development
5.3.3. Dosage Form, Regimen and Price
5.3.4. Historical Sales
5.3.5. Current Status of Development
5.3.6. Key Clinical Trial Results
5.3.6.1. AWARD-1
5.3.6.2. AWARD-2
5.3.6.3. AWARD-3
5.3.6.4. AWARD-4
5.3.6.5. AWARD-5
5.3.6.6. AWARD-6
5.3.6.7. AWARD-8
5.3.6.8. AWARD-9
5.3.6.9. Trulicity® versus Lantus®
5.3.6.10. Trulicity® versus Victoza®
5.3.7. Recent Collaborations
5.4. ITCA 650 (Intarcia Therapeutics / Servier)
5.4.1. Product Overview
5.4.2. History of Development
5.4.3. Intarcia’s Technology Platform
5.4.4. Current Status of Development
5.4.5. Key Clinical Trial Results
5.4.5.1. FREEDOM 1 HBL: Interim Results
5.4.5.2. FREEDOM-1 and FREEDOM-1 HBL: Top-Line Results
5.4.5.3. FREEDOM-2 Comparative Trial: Top-Line Results
5.4.5.4. FREEDOM-CVO: Top-Line Results
5.4.6. Funding
5.4.7. Recent Collaborations
5.5. Polyethylene Glycol Loxenatide / PEX 168 (Jiangsu Hansoh Pharmaceutical)
5.5.1. Product Overview
5.5.2. Current Status of Development
5.5.3. Key Clinical Trial Results
5.6. Semaglutide / NN9535 / NN9924 / OG217SC (Novo Nordisk/Emisphere)
5.6.1. Product Overview
5.6.2. History of Development
5.6.3. NN9924 and the Eligen® Technology
5.6.4. Manufacturing
5.6.5. Dosage Form and Regimen
5.6.6. Current Status of Development
5.6.6.1. PIONEER Clinical Program
5.6.6.2. SUSTAIN Clinical Program
5.6.7. Key Clinical Trial Results
5.6.7.1. NN9535: Phase III Results
5.6.7.2. NN9924/OG217SC: Phase II Results
5.6.8. Recent Collaborations
5.7. Uni-E4 (Uni-Bio Science Group)
5.7.1. Product Overview
5.7.2. Key Clinical Trial Results
6. DPP4 Inhibitors / CD26 Antigen Antagonists
6.1. Chapter Overview
6.2. Alogliptin (Takeda / Furiex Pharmaceuticals (Acquired by Forest Laboratories))
6.2.1. Product Overview
6.2.2. History of Development
6.2.3. Dosage Form, Regimen and Price
6.2.4. Historical Sales
6.2.5. Current Status of Development
6.2.6. Key Clinical Trial Results
6.2.6.1. EXAMINE Program
6.2.6.2. ENDURE Trial
6.2.7. Recent Collaborations
6.3. Trelagliptin (Takeda / 3SBio)
6.3.1. Product Overview
6.3.2. History of Development
6.3.3. Dosage Form, Regimen and Price
6.3.4. Current Status of Development
6.3.5. Key Clinical Trial Results
6.3.6. Recent Collaborations
6.4. Omarigliptin (Merck)
6.4.1. Product Overview
6.4.2. History of Development
6.4.3. Current Status of Development
6.4.4. Key Clinical Trial Results
6.5. Evogliptin (Dong-A Pharmaceutical / Luye Pharma Group / Eurofarma / Geropharm / Alkem Labs)
6.5.1. Product Overview
6.5.2. Dosage Forms, Regimen and Price
6.5.3. Current Status of Development
6.5.4. Key Clinical Trial Results
6.5.5. Recent Collaborations
6.6. Gosogliptin (SatRx / Pfizer)
6.6.1. Product Overview
6.6.2. Current Status of Development
6.6.3. Recent Collaborations
6.7. Retagliptin (Jiangsu Hengrui Medicine)
6.7.1. Product Overview
6.7.2. Current Status of Development
7. SGLT2 Inhibitors
7.1. Chapter Overview
7.2. Canagliflozin (Mitsubishi Tanabe Pharma / Janssen / Daiichi Sankyo)
7.2.1. Product Overview
7.2.2. History of Development
7.2.3. Dosage Form, Regimen and Price
7.2.4. Historical Sales
7.2.5. Current Status of Development
7.2.6. Key Clinical Trial Results
7.2.6.1. Long Term Effects in Older Type II Diabetic Patients
7.2.6.2. Real-World Analysis
7.2.6.3. Comparison between INVOKANA® and Other DPP4 Inhibitors
7.2.7. Recent Collaborations
7.3. Luseogliflozin (Taisho Pharmaceutical / Taisho Toyama Pharmaceutical / Novartis)
7.3.1. Product Overview
7.3.2. History of Development
7.3.3. Dosage Form, Regimen and Price
7.3.4. Current Status of Development
7.3.5. Key Clinical Trial Results
7.3.5.1. As a Monotherapy
7.3.5.1.1. Study 1: Placebo Controlled (24 weeks)
7.3.5.1.2. Study 2: Long-Term Treatment (52 weeks)
7.3.5.2. As Combination Therapy
7.3.5.2.1. Study 1: Combination with Glimepiride
7.3.5.2.2. Study 2: Combination with Metformin, DPP4 inhibitor, Pioglitazone, Glinides or alpha-glucosidase inhibitor
7.3.6. Historical Sales
7.3.7. Recent Collaborations
7.4. Tofogliflozin (Chugai Pharmaceutical / Sanofi / Kowa)
7.4.1. Product Overview
7.4.2. History of Development
7.4.3. Current Status of Development
7.4.4. Key Clinical Trial Results
7.4.4.1. As a Monotherapy
7.4.5. Recent Collaborations
7.5. Empagliflozin (Boehringer Ingelheim / Eli Lilly)
7.5.1. Product Overview
7.5.2. History of Development
7.5.3. Dosage Form, Regimen and Price
7.5.4. Manufacturing
7.5.5. Current Status of Development
7.5.6. Key Clinical Trial Results
7.5.6.1. As a Monotherapy: Retrospective Data
7.5.6.2. As a Fixed-Dose Combination Therapy
7.5.6.2.1. Combination with Metformin
7.5.6.2.2. Combination with Linagliptin
7.5.6.3. CV Outcome Results (EMPA-REG OUTCOME®)
7.5.7. Recent Collaborations
7.6. Ipragliflozin (Astellas Pharma / Kotobuki Pharmaceutical / MSD K.K.)
7.6.1. Product Overview
7.6.2. History of Development
7.6.3. Dosage Form, Regimen and Price
7.6.4. Current Status of Development
7.6.5. Key Clinical Trial Results
7.6.5.1. As a Monotherapy
7.6.5.2. As a Combination Therapy
7.6.6. Recent Collaborations
7.7. Bexagliflozin (Theracos)
7.7.1. Product Overview
7.7.2. Current Status of Development
7.7.3. Key Clinical Trial Results
7.8. Ertugliflozin (PF-04971729, MK-8835) (Pfizer /Merck)
7.8.1. Product Overview
7.8.2. Current Status of Development
7.8.3. Key Clinical Trial Results
7.8.3.1. As a Monotherapy: VERTIS Mono
7.8.3.2. As a Combination Therapy with JANUVIA®: VERTIS Factorial
7.8.4. Recent Collaborations
7.9. Sotagliflozin (Lexicon/Sanofi)
7.9.1. Product Overview
7.9.2. History of Development
7.9.3. Current Status of Development
7.9.4. Key Clinical Trial Results
7.9.4.1. Type I Diabetes: Phase II Results
7.9.4.2. Type II Diabetes: Phase IIb Results
7.9.4.3. Type II Diabetes: Phase IIa Results
7.9.4.4. Type I Diabetes / Type II Diabetes with Renal Impairment
7.9.4.5. As a Combination Therapy
7.9.5. Recent Collaborations
8. Discontinued Molecules and Common Side Effects
8.1. Chapter Overview
8.2. DPP4 Inhibitors
8.2.1. Common Side Effects
8.2.2. Warnings Issued by Regulatory Agencies
8.3. SGLT2 Inhibitors
8.3.1. Common Side Effects
8.3.2. Warnings issued by Regulatory Agencies
8.4. GLP-1 Agonists
8.4.1. Common Side Effects
8.4.2. Warnings Issued by Regulatory Agencies
8.5. DPP4 Inhibitors, GLP-1 Agonists, SGLT2 Inhibitors: Terminated Molecules
8.5.1. Distribution by Type of Drug Class and Phase of Development
8.5.2. Distribution by Year of Termination
9. Novel Non-Insulin Therapies for Diabetes
9.1. Chapter Overview
9.2. Novel Non-Insulin Therapies for Diabetes
9.2.1. Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Drug Class
9.2.2. Novel Non-Insulin Therapies for Diabetes: Distribution by Phase of Development
9.2.3. Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Molecule
10. Market Forecast
10.1. Chapter Overview
10.2. Forecast Methodology
10.3. Overall Non-Insulin Therapies for Diabetes Market
10.4. Overall GLP-1 Agonists Market
10.4.1. Liraglutide (1.2mg and 1.8mg)
10.4.2. Exendin-4 / ITCA 650
10.4.3. Exenatide Extended Release
10.4.4. Dulaglutide
10.4.5. Albiglutide
10.4.6. Lixisenatide
10.4.7. Semaglutide Subcutaneous
10.4.8. Liraglutide / Insulin Degludec
10.4.9. Semaglutide Oral / OG217SC / NN9924
10.4.10. Exenatide
10.4.11. Other GLP-1 Agonists
10.5. Overall DPP4 Inhibitors Market
10.5.1. Sitagliptin
10.5.2. Vildagliptin
10.5.3. Saxagliptin
10.5.4. Linagliptin
10.5.5. Alogliptin
10.5.6. Gosogliptin
10.5.7. Other DPP4 Inhibitors
10.6. Overall SGLT2 Inhibitors Market
10.6.1. Sotagliflozin
10.6.2. Empagliflozin
10.6.3. Canagliflozin
10.6.4. Dapagliflozin
10.6.5. Tofogliflozin
10.6.6. Ertugliflozin
10.6.7. Bexagliflozin
10.6.8. Other SGLT2 Inhibitors
11. Publication Analysis
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. GLP-1 Agonists: List of Publications
11.3.1. Publications on GLP-1 Agonists: Distribution by Focus Drug
11.3.2. Publications on GLP-1 Agonists: Distribution by Key Parameters
11.4. DPP4 Inhibitors: List of Publications
11.4.1. Publications on DPP4 Inhibitors: Distribution by Focus Drug
11.4.2. Publications on DPP4 Inhibitors: Distribution by Key Parameters
11.5. SGLT2 Inhibitors: List of Publications
11.5.1. Publications on SGLT2 Inhibitors: Distribution by Focus Drug
11.5.2. Publications on SGLT2 Inhibitors: Distribution by Key Parameters
12. KOL Analysis
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. GLP-1 Agonists: Key Opinion Leaders
12.3.1. GLP-1 Agonists: Prominent Researchers
12.3.2. GLP-1 Agonists: Leading Key Opinion Leaders
12.4. DPP4 Inhibitors: Key Opinion Leaders
12.4.1. DPP4 Inhibitors: Prominent Researchers
12.4.2. DPP4 Inhibitors: Leading Key Opinion Leaders
12.5. SGLT2 Inhibitors: Key Opinion Leaders
12.5.1. SGLT2 Inhibitors: Prominent Researchers
12.5.2. SGLT2 Inhibitors: Leading Key Opinion Leaders
13. Interview Transcripts
14. Conclusion
14.1. The Lucrative Anti-Diabetic Drugs Market Presents Immense Opportunity to Novel Non-Insulin Therapies
14.2. GLP-1 Inhibitors and DPP4 Inhibitors Currently Dominate; SGLT2 Inhibitors Have Shown Significant Promise
14.3. Companies Targeting Certain Regional Markets are Amongst the Primary Drivers
14.4. Technological Advances and Innovative Drug Development Approaches are Key to Future Success
14.5. Development of Combination Therapies and Several Novel Drug Classes Are Expected to Promote Future Growth
14.6. Multiple Side Effects Associated with the Use of Certain Drug Classes Remain a Concern
14.7. While the Respective Shares of GLP-1 Agonists and SGLT2 Inhibitors are Projected to Increase, Sales of DPP4 Inhibitors Are Likely to Dip
15. Appendix 1: Tabulated Data
16. Appendix 2: List of Companies and Organizations
LIST OF FIGURES
Figure 3.1 Diabetes: Diagnostic Limits
Figure 3.2 Non-Insulin Therapies for Diabetes
Figure 4.1 Non-Insulin Therapies: Distribution by Drug Class
Figure 4.2 GLP-1 Agonists: Distribution by Phase of Development
Figure 4.3 GLP-1 Agonists: Key Players
Figure 4.4 GLP-1 Agonists: Distribution by Route of Administration
Figure 4.5 GLP-1 Agonists: Distribution by Dosage Frequency
Figure 4.6 GLP-1 Agonists: Distribution by Type of Molecule
Figure 4.7 DPP4 Inhibitors: Distribution by Phase of Development
Figure 4.8 DPP4 Inhibitors: Key Players
Figure 4.9 DPP4 Inhibitors: Distribution by Type of Therapy
Figure 4.10 DPP4 Inhibitors: Distribution by Dosage Frequency
Figure 4.11 SGLT2 Inhibitors: Distribution by Phase of Development
Figure 4.12 SGLT2 Inhibitors: Key Players
Figure 4.13 SGLT2 Inhibitors: Distribution by Type of Therapy
Figure 4.14 SGLT2 Inhibitors: Distribution by Dosage Frequency
Figure 4.15 GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors: Key Players
Figure 5.1 Tanzeum® / Eperzan®: Historical Sales, 2014-Q12016 (GBP Million)
Figure 5.2 Trulicity®: Historical Sales, 2014-2015 (USD Million)
Figure 5.3 Trulicity® Historical Sales: Distribution by Region, 2015 (USD Million)
Figure 5.4 ITCA 650: FREEDOM-1 and FREDDOM-1 HBL Clinical Trials
Figure 6.1 Alogliptin: History of Development
Figure 6.2 Alogliptin: Historical Sales, FY2011-Q1 FY2016 (JPY Billion)
Figure 6.3 Alogliptin Historical Sales: Distribution by Region, FY2015 (JPY Billion)
Figure 7.1 Canagliflozin: History of Development
Figure 7.2 INVOKANA® / INVOKAMET®: Historical Sales, 2013-Q1 2016 (USD Million)
Figure 7.3 INVOKANA® / INVOKAMET® Historical Sales: Distribution by Region, 2015-Q1 2016 (USD Million)
Figure 7.4 Empagliflozin: History of Development
Figure 7.5 Ipragliflozin: History of Development
Figure 8.1 Terminated Molecules: Distribution by Type of Drug Class
Figure 8.2 Terminated Molecules: Distribution by Type of Drug Class and Phase of Development
Figure 8.3 Terminated Molecules: Distribution by Type of Drug Class and Year of Termination
Figure 9.1 Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Drug Class
Figure 9.2 Novel Non-Insulin Therapies for Diabetes: Distribution by Phase of Development
Figure 9.3 Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Molecule
Figure 10.1 Non-Insulin Therapies for Diabetes Market, 2016-2026 (USD Billion)
Figure 10.2 Non-Insulin Therapies for Diabetes Market, 2016-2026: Future Trends and Details
Figure 10.3 Non-Insulin Therapies for Diabetes Market, 2016, 2021 and 2026: Distribution by Type of Drug Class
Figure 10.4 GLP-1 Agonists Market, 2016-2026 (USD Billion)
Figure 10.5 Liraglutide (1.2mg and 1.8mg) Sales Forecast, 2016-2026 (USD Million)
Figure 10.6 Exendin-4 / ITCA 650 Sales Forecast, 2017-2026 (USD Million)
Figure 10.7 Exenatide Extended Release Sales Forecast, 2016-2026 (USD Million)
Figure 10.8 Dulaglutide Sales Forecast, 2016-2026 (USD Million)
Figure 10.9 Albiglutide Sales Forecast, 2016-2026 (USD Million)
Figure 10.10 Lixisenatide Sales Forecast, 2016-2026 (USD Million)
Figure 10.11 Semaglutide/NN9535 Sales Forecast, 2018-2026 (USD Million)
Figure 10.12 Liraglutide / Insulin Degludec Sales Forecast, 2016-2026 (USD Million)
Figure 10.13 Semaglutide Oral / OGC217SC / NN9924 Sales Forecast, 2020-2026 (USD Million)
Figure 10.14 Exenatide Sales Forecast, 2016-2026 (USD Million)
Figure 10.15 DPP4 Inhibitors Market, 2016-2026 (USD Billion)
Figure 10.16 Sitagliptin Sales Forecast, 2016-2026 (USD Million)
Figure 10.17 Vildagliptin Sales Forecast, 2016-2026 (USD Million)
Figure 10.18 Saxagliptin Sales Forecast, 2016-2026 (USD Million)
Figure 10.19 Linagliptin Sales Forecast, 2016-2026 (USD Million)
Figure 10.20 Alogliptin Sales Forecast, 2016-2026 (USD Million)
Figure 10.21 Gosogliptin Sales Forecast, 2017-2026 (USD Million)
Figure 10.22 SGLT2 Inhibitors Market, 2016-2026 (USD Billion)
Figure 10.23 Sotagliflozin Sales Forecast, 2018-2026 (USD Million)
Figure 10.24 Empagliflozin Sales Forecast, 2016-2026 (USD Million)
Figure 10.25 Canagliflozin Sales Forecast, 2016-2026 (USD Million)
Figure 10.26 Dapagliflozin Sales Forecast, 2016-2026 (USD Million)
Figure 10.27 Tofogliflozin Sales Forecast, 2016-2026 (USD Million)
Figure 10.28 Ertugliflozin Sales Forecast, 2018-2026 (USD Million)
Figure 10.29 Bexagliflozin Sales Forecast, 2018-2026 (USD Million)
Figure 11.1 Publications on GLP-1 Agonists: Distribution by Focus Drug
Figure 11.2 Publications on GLP-1 Agonists: Distribution by Study Focus, Publication Month and other Parameters
Figure 11.3 Publications on DPP4 Inhibitors: Distribution by Focus Drug
Figure 11.4 Publications on DPP4 Inhibitors: Distribution by Study Focus, Publication Month and other Parameters
Figure 11.5 Publications on SGLT2 Inhibitors: Distribution by Focus Drug
Figure 11.6 Publications on SGLT2 Inhibitors: Distribution by Study Focus, Publication Month and other Parameters
Figure 12.1 GLP-1 Agonists: Mapping Prominent Researchers
Figure 12.2 GLP-1 Agonists: Leading Key Opinion Leaders
Figure 12.3 DPP4 Inhibitors: Mapping Prominent Researchers
Figure 12.4 DPP4 inhibitors: Leading Key Opinion Leaders
Figure 12.5 SGLT2 Inhibitors: Mapping Prominent Researchers
Figure 12.6 SGLT2 Inhibitors: Leading Key Opinion Leaders
Figure 14.1 Overall Non-Insulin Therapies Market Forecast: Distribution by Drug Class, 2016-2026 (USD Billion)
LIST OF TABLES
Table 4.1 Anti-Diabetic Drug Classes: History of Development
Table 4.2 GLP-1 Agonists: Approved Drugs
Table 4.3 GLP-1 Agonists: Pipeline Drugs
Table 4.4 DPP4 Inhibitors: Approved Drugs
Table 4.5 DPP4 Inhibitors: Pipeline Drugs
Table 4.6 SGLT2 Inhibitors: Approved Drugs
Table 4.7 SGLT2 Inhibitors: Pipeline Drugs
Table 5.1 Albiglutide: Product Overview
Table 5.2 Albiglutide: Active / Planned Clinical Trials
Table 5.3 Albiglutide Harmony 2 Clinical Trial: Adverse Events
Table 5.4 Albiglutide Harmony 3 Clinical Trial: Adverse Events
Table 5.5 Albiglutide Harmony 4 Clinical Trial: Adverse Events
Table 5.6 Albiglutide Harmony 5 Clinical Trial: Adverse Events
Table 5.7 Albiglutide Harmony 6 Clinical Trial: Results
Table 5.8 Albiglutide Harmony 6 Clinical Trial: Adverse Events
Table 5.9 Albiglutide Harmony 7 Clinical Trial: Results
Table 5.10 Albiglutide Harmony 7 Clinical Trial: Adverse Events
Table 5.11 Dulaglutide: Product Overview
Table 5.12 Trulicity®: Active / Planned Clinical Trials
Table 5.13 Trulicity®: AWARD Clinical Program Results
Table 5.14 Trulicity®: AWARD-1 Clinical Trial Results
Table 5.15 Trulicity®: AWARD-2 Clinical Trial Results
Table 5.16 Trulicity®: AWARD-3 Clinical Trial Results
Table 5.17 Trulicity®: AWARD-4 Clinical Trial Results
Table 5.18 Trulicity®: AWARD-5 Clinical Trial Results
Table 5.19 Trulicity®: AWARD-6 Clinical Trial Results
Table 5.20 Trulicity®: AWARD-9 Clinical Trial Results
Table 5.21 Trulicity® versus Lantus®: Phase III Clinical Trial Results
Table 5.22 Trulicity® versus Lantus®: Phase III Clinical Trial Adverse Events
Table 5.23 Trulicity® versus Victoza®: Phase III Clinical Trial Results
Table 5.24 Trulicity® versus Victoza®: Phase III Clinical Trial Adverse Events
Table 5.25 ITCA 650: FREEDOM Clinical Trial Development Program
Table 5.26 ITCA 650: Active / Planned Clinical Trials
Table 5.27 ITCA 650: FREEDOM-2 Clinical Trial Results
Table 5.28 PEX 168: Active / Planned Clinical Trials
Table 5.29 PEX 168: Clinical Trial Results
Table 5.30 Semaglutide: Active / Planned Clinical Trials
Table 5.31 Semaglutide: SUSTAIN Clinical Program Key Characteristics
Table 5.32 Semaglutide: SUSTAIN 1 Clinical Trial Results
Table 5.33 Semaglutide: SUSTAIN 1 Clinical Trial Adverse Events
Table 5.34 Semaglutide: SUSTAIN 3 Clinical Trial Results
Table 5.35 Semaglutide: SUSTAIN 2 Clinical Trial Results
Table 5.36 Semaglutide: SUSTAIN 5 Clinical Trial Results
Table 5.37 Semaglutide: SUSTAIN 4 Clinical Trial Results
Table 5.38 Semaglutide: SUSTAIN 4 Clinical Trial Adverse Events
Table 5.39 Uni-E4: Phase III Clinical Trial Results
Table 6.1 Alogliptin: Product Overview
Table 6.2 Alogliptin: Dosage Form, Regimen and Price
Table 6.3 Alogliptin: Active / Planned Clinical Trials
Table 6.4 Alogliptin EXAMINE Program: Dose and % Recipient Population
Table 6.5 Alogliptin ENDURE Trial: Drug and Dosage Combinations
Table 6.6 Trelagliptin: Active / Planned Clinical Trials
Table 6.7 Omarigliptin: Phase III Clinical Trial Adverse Events
Table 6.8 Evogliptin: Active / Planned Clinical Trials
Table 6.9 Evogliptin: Phase II Clinical Trial Results
Table 6.10 Retagliptin: Active / Planned Clinical Trials
Table 7.1 Canagliflozin: Product Overview
Table 7.2 Canagliflozin: Dosage Form, Regimen and Price
Table 7.3 Canagliflozin: Active / Planned Clinical Trials
Table 7.4 Canagliflozin as Monotherapy in Older Type II Diabetic Patients: Phase III Clinical Trial Results
Table 7.5 INVOKANA®: First Real-World Analysis
Table 7.6 INVOKANA®: Second Real-World Analysis
Table 7.7 INVOKANA®: Third Real-World Analysis
Table 7.8 Luseogliflozin: Active / Planned Trials
Table 7.9 Tofogliflozin: Active / Planned Clinical Trials
Table 7.10 Empagliflozin: Product Overview
Table 7.11 Empagliflozin: Dosage Form, Regime and Price
Table 7.12 Empagliflozin: Active / Planned Clinical Trials
Table 7.13 Empagliflozin: Retrospective Data (After 12 weeks)
Table 7.14 Empagliflozin: Retrospective Data (After 24 weeks)
Table 7.15 Glyxambi®: Phase III Clinical Trial Results
Table 7.16 Glyxambi®: Phase III Clinical Trial Adverse Events
Table 7.17 Ipragliflozin: Active / Planned Clinical Trials
Table 7.18 Ipragliflozin as Combination Therapy: Phase III Clinical Trial Results
Table 7.19 Bexagliflozin: Phase II Clinical Trial Results
Table 7.20 Ertugliflozin: Active/Planned Clinical Trials
Table 7.21 Ertugliflozin: Phase III Clinical Trial Results (VERTIS Mono)
Table 7.22 Ertugliflozin: Phase III Clinical Trial Adverse Events (VERTIS Mono)
Table 7.23 Ertugliflozin: Phase III Clinical Trial Results (VERTIS Factorial)
Table 7.24 Ertugliflozin: Phase III Clinical Trial Adverse Events (VERTIS Factorial)
Table 7.25 Sotagliflozin: Active/Planned Clinical Trials
Table 7.26 Sotagliflozin: Phase IIb Study Results, Reduction in HbA1c levels
Table 7.27 Sotagliflozin: Phase IIb Study Results, Reduction in Blood Pressure
Table 7.28 Sotagliflozin: Phase IIa Study Results
Table 8.1 DPP4 Inhibitors: Regulatory Agencies Warnings
Table 8.2 SGLT2 Inhibitors: Regulatory Agencies Warnings
Table 8.3 DPP4 inhibitors/SGLT2 inhibitors/GLP-1 Agonists: Terminated Molecules
Table 9.1 List of Novel Non-Insulin Therapies for Diabetes
Table 11.1 GLP-1 Agonists: List of Publications
Table 11.2 DPP4 Inhibitors: List of Publications
Table 11.3 SGLT2 Inhibitors: List of Publications
Table 12.1 GLP-1 Agonists: List of Key Opinion Leaders
Table 12.2 DPP4 Inhibitors: List of Key Opinion Leaders
Table 12.3 SGLT2 inhibitors: List of Key Opinion Leaders
Table 15.1 Non-Insulin Therapies: Distribution by Drug Class
Table 15.2 GLP-1 Agonists: Distribution by Phase of Development
Table 15.3 GLP-1 Agonists: Key Players
Table 15.4 GLP-1 Agonists: Distribution by Route of Administration
Table 15.5 GLP-1 Agonists: Distribution by Dosage Frequency
Table 15.6 GLP-1 Agonists: Distribution by Type of Molecule
Table 15.7 DPP4 Inhibitors: Distribution by Phase of Development
Table 15.8 DPP4 Inhibitors: Key Players
Table 15.9 DPP4 Inhibitors: Distribution by Type of Therapy
Table 15.10 DPP4 Inhibitors: Distribution by Dosage Frequency
Table 15.11 SGLT2 Inhibitors: Distribution by Phase of Development
Table 15.12 SGLT2 Inhibitors: Key Players
Table 15.13 SGLT2 Inhibitors: Distribution by Type of Therapy
Table 15.14 SGLT2 Inhibitors: Distribution by Dosage Frequency
Table 15.15 GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors: Key Players
Table 15.16 Tanzeum® / Eperzan®: Historical Sales, 2014-Q12016 (GBP Million)
Table 15.17 Trulicity®: Historical Sales, 2014-2015 (USD Million)
Table 15.18 Trulicity® Historical Sales: Distribution by Region, 2015 (USD Million)
Table 15.19 Alogliptin: Historical Sales, FY2011-Q1 FY2016 (JPY Billion)
Table 15.20 Alogliptin Historical Sales: Distribution by Region, FY2015 (JPY Billion)
Table 15.21 INVOKANA® / INVOKAMET®: Historical Sales, 2013-Q1 2016 (USD Million)
Table 15.22 INVOKANA® / INVOKAMET® Historical Sales: Distribution by Region, 2015-Q1 2016 (USD Million)
Table 15.23 Terminated Molecules: Distribution by Type of Drug Class
Table 15.24 Terminated Molecules: Distribution by Type of Drug Class and Phase of Development
Table 15.25 Terminated Molecules: Distribution by Type of Drug Class and Year of Termination
Table 15.26 Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Drug Class
Table 15.27 Novel Non-Insulin Therapies for Diabetes: Distribution by Phase of Development
Table 15.28 Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Molecule
Table 15.29 Non-Insulin Therapies for Diabetes Market, 2016-2026 (USD Billion)
Table 15.30 Non-Insulin Therapies for Diabetes Market, 2016, 2021 and 2026: Distribution by Type of Drug Class
Table 15.31 GLP-1 Agonists Market, 2016-2026 (USD Billion)
Table 15.32 Liraglutide (1.2mg and 1.8mg) Sales Forecast, 2016-2026 (USD Million)
Table 15.33 Exendin-4 / ITCA 650 Sales Forecast, 2017-2026 (USD Million)
Table 15.34 Exenatide Extended Release Sales Forecast, 2016-2026 (USD Million)
Table 15.35 Dulaglutide Sales Forecast, 2016-2026 (USD Million)
Table 15.36 Albiglutide Sales Forecast, 2016-2026 (USD Million)
Table 15.37 Lixisenatide Sales Forecast, 2016-2026 (USD Million)
Table 15.38 Semaglutide/NN9535 Sales Forecast, 2018-2026 (USD Million)
Table 15.39 Liraglutide / Insulin Degludec Sales Forecast, 2016-2026 (USD Million)
Table 15.40 Semaglutide Oral / OGC217SC / NN9924 Sales Forecast, 2020-2026 (USD Million)
Table 15.41 Exenatide Sales Forecast, 2016-2026 (USD Million)
Table 15.42 DPP4 Inhibitors Market, 2016-2026 (USD Billion)
Table 15.43 Sitagliptin Sales Forecast, 2016-2026 (USD Million)
Table 15.44 Vildagliptin Sales Forecast, 2016-2026 (USD Million)
Table 15.45 Saxagliptin Sales Forecast, 2016-2026 (USD Million)
Table 15.46 Linagliptin Sales Forecast, 2016-2026 (USD Million)
Table 15.47 Alogliptin Sales Forecast, 2016-2026 (USD Million)
Table 15.48 Gosogliptin Sales Forecast, 2017-2026 (USD Million)
Table 15.49 SGLT2 Inhibitors Market, 2016-2026 (USD Billion)
Table 15.50 Sotagliflozin Sales Forecast, 2018-2026 (USD Million)
Table 15.51 Empagliflozin Sales Forecast, 2016-2026 (USD Million)
Table 15.52 Canagliflozin Sales Forecast, 2016-2026 (USD Million)
Table 15.53 Dapagliflozin Sales Forecast, 2016-2026 (USD Million)
Table 15.54 Tofogliflozin Sales Forecast, 2016-2026 (USD Million)
Table 15.55 Ertugliflozin Sales Forecast, 2018-2026 (USD Million)
Table 15.56 Bexagliflozin Sales Forecast, 2018-2026 (USD Million)
Table 15.57 Publications on GLP-1 Agonists: Distribution by Focus Drug
Table 15.58 Publications on DPP4 Inhibitors: Distribution by Focus Drug
Table 15.59 Publications on SGLT2 Inhibitors: Distribution by Focus Drug
Table 15.60 Overall Non-Insulin Therapies Market Forecast: Distribution by Drug Class, 2016-2026 (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report